SKHY

SKHY maintains its Stage 2 uptrend with rising 9-, 20-, and 50-day EMAs supporting higher highs and lows, but the recent gap above the EMAs into extreme overbought territory offers no immediate entry. Under the Compounders approach, patient stalking for a pullback into the 9- and 20-day EMA zone (~162–159) provides a structurally favorable interaction area for tactical long exposure.

• ↑Q2 revenue hit ₩79,318.7B (+257% YoY) with 76% operating margin.
• ↑Announced ₩40T (~$29B) share buyback highlighting strong cash generation.
• ↓High share price volatility signals potential sharp price swings.